Smith & Nephew SNATS, Inc. (NYSE:SNN) has been assigned an average rating of “Buy” from the nine brokerages that are currently covering the stock, MarketBeat.com reports. Four investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $42.50.

Several research firms have recently commented on SNN. Zacks Investment Research upgraded Smith & Nephew SNATS from a “hold” rating to a “buy” rating and set a $43.00 price objective on the stock in a report on Wednesday. Canaccord Genuity began coverage on Smith & Nephew SNATS in a report on Wednesday, October 11th. They issued a “buy” rating and a $42.00 price objective on the stock. Finally, BidaskClub upgraded Smith & Nephew SNATS from a “hold” rating to a “buy” rating in a report on Tuesday, August 1st.

Shares of Smith & Nephew SNATS (NYSE:SNN) traded up 0.95% during midday trading on Friday, hitting $38.28. The stock had a trading volume of 884,798 shares. Smith & Nephew SNATS has a 1-year low of $26.97 and a 1-year high of $40.43. The stock has a market cap of $16.76 billion, a price-to-earnings ratio of 19.49 and a beta of 0.74. The firm’s 50-day moving average price is $36.82 and its 200-day moving average price is $35.01.

The firm also recently declared a semiannual dividend, which will be paid on Wednesday, November 1st. Investors of record on Friday, October 6th will be issued a dividend of $0.246 per share. The ex-dividend date is Thursday, October 5th. This represents a yield of 1.37%.

COPYRIGHT VIOLATION NOTICE: “Smith & Nephew SNATS, Inc. (SNN) Given Average Recommendation of “Buy” by Brokerages” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/22/smith-nephew-snats-inc-snn-given-average-recommendation-of-buy-by-brokerages.html.

A number of large investors have recently made changes to their positions in SNN. Paloma Partners Management Co purchased a new position in Smith & Nephew SNATS during the 1st quarter valued at about $200,000. Greenleaf Trust purchased a new position in Smith & Nephew SNATS during the 2nd quarter valued at about $207,000. HighTower Advisors LLC purchased a new position in Smith & Nephew SNATS during the 1st quarter valued at about $242,000. Quantbot Technologies LP increased its holdings in Smith & Nephew SNATS by 270.0% during the 2nd quarter. Quantbot Technologies LP now owns 7,277 shares of the medical equipment provider’s stock valued at $253,000 after purchasing an additional 5,310 shares during the period. Finally, The Manufacturers Life Insurance Company increased its holdings in Smith & Nephew SNATS by 0.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 7,437 shares of the medical equipment provider’s stock valued at $260,000 after purchasing an additional 63 shares during the period. Institutional investors own 6.37% of the company’s stock.

About Smith & Nephew SNATS

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.

Analyst Recommendations for Smith & Nephew SNATS (NYSE:SNN)

Receive News & Ratings for Smith & Nephew SNATS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew SNATS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.